Latest Breaking News On - புற்றுநோயியல் ஆராய்ச்சி ப்ரோக்ர்யாம் - Page 1 : comparemela.com

 E-Mail IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer. view more  Credit: Huntsman Cancer Institute PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021. Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose in

Colorado
United-states
Dana-farber-cancer-institute
Massachusetts
Megan-othus
Justinev-cohen
Johnm-kirkwood
Teresam-petrella
Antoni-ribas
Bartosz-chmielowski
Kennethf-grossmann
Kari-kendra